Preoxygenation for Difficult Airway Management

Intubation;Difficult Clinical Trial

— PREOPTI-DAM  

Official title:

PREOPTI-DAM: High-flow Nasal Cannula Oxygen Versus Standard Oxygenation During Intubation for Patient at Risk of Difficult Intubation: A Randomized Controlled Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03604120
• Other study ID #: RC17_0474
• Status: Completed
• Phase: N/A
• Start date: September 19, 2018
• Est. completion date: March 8, 2021

Study information

• Verified date: May 2021
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Tracheal intubation in operating room for patients at risk of difficult intubation remains a critical event. The aim of this study is to determine whether Nasal High Flow Therapy by nasal cannula Optiflow® administered before and during intubation is more efficient than the standard care for pre-oxygenation and oxygenation during anticipated difficult intubation

Description:

This study will be designed as followed: Patients will be randomized in 2 groups:

• Preoxygenation during 4 minutes with High Flow Nasal Cannula (60l/min FiO2 = 1) before and during intubation. The device will be maintained in place throughout the intubation procedure (including fiber-optic or laryngoscopic) in order to achieve oxygenation.

• Or Standard Preoxygenation during 4 minutes with FIBROXY® (Fiber-optic intubation) or standard facial mask (Laryngoscopic intubation), at FiO2=100%. FIBROXY mask will be maintained in place during the fiberoptic procedure. Standard facial mask, will be removed after the crash induction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 186
• Est. completion date: March 8, 2021
• Est. primary completion date: March 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients 18 years of aged and over

• And anticipated difficult intubation

• And requiring a rapid sequence induction for laryngoscopic intubation

• Or requiring a fiberoptic intubation

Exclusion Criteria:

• BMI > 35

• Pulse oxymetry < 90% in ambient air

• Haemodynamic instability

• Pregnancy

• Protected adult

• Lack of consent

• Patient already enrolled in another randomized study looking forward improving preoxygenation quality.

Related Conditions & MeSH terms

• Intubation;Difficult

Intervention

Device:
• Preoxygenation with high flow therapy by nasal cannula
Preoxygenation during 4 minutes with High Flow Nasal Cannula (60l/min FiO2 = 1) before fiber-optic or laryngoscopic intubation. The device will be maintained in place throughout the intubation procedure in order to achieve oxygenation.
• Preoxygenation by standard Facial mask
For Fiber-optic intubation: patients will receive a 4 minutes FIBROXY facial mask preoxygenation with FiO2=100%. The FIBROXY facial mask will be maintained in place during the intubation procedure. For Laryngoscopic intubation: patients will receive a 4 minutes standard facial mask preoxygenation with FiO2=100%. The standard facial mask will be removed after crash induction to proceed to intubation.

Locations

Country	Name	City	State
France	Nantes University Hospital	Nantes

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of desaturation below 95% or manual facial mask reventilation during ETI procedure.	To determine whether High-Flow nasal cannula used for preoxygenation and oxygenation during intubation, is more efficient than standard care during difficult intubation. This outcome will be assessed from the beginning of the preoxygenation period to the end of orotracheal intubation by monitoring the pulse oxymetry.	4 minutes
Secondary	Improvement of quality of preoxygenation	duration of proceedings	4 minutes
Secondary	Reduction in side effects incidence related to intubation		6 hours
Secondary	Morbi-mortality during surgery.	Per and postoperative complication rate	6 hours